VKVira Mykhaylivna Kulaiets

Vira Mykhaylivna Kulaiets

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vira Mykhaylivna Kulaiets has a total of 5 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The value of biomarkers in predicting the course of heart failure of ischemic genesis in patients with atrial fibrillation and diabetes mellitus

    by Nadiia Mykhailivna Kulaiets, Vira Mykhaylivna Kulaiets

    Aim: To study the prognostic value of biomarkers in patients with heart failure of ischemic origin with concomitant atrial fibrillation and diabetes mellitus.Material and methods: 398 patients with heart failure (HF) on the background of post-infarction cardiosclerosis (198 women and 200 men) were included in the study. Patients were divided into 3 groups depending on the HF phenotype: Group I – 167 (42.0%) patients who had reduced LV EF (≤ 40%); II group – 133 (33.4%) patients with moderately reduced LV EF (41-49%); Group III – 98 (24.6%) patients with preserved LV EF (≥ 50%).Results: In HF patients with reduced LVEF, compared to patients who had moderately reduced and preserved FE, IV FK according to NYHA and AF are more often diagnosed 70.1%, against 53.4% and 38.8%; 2 = 25.57, p = 0.0001); higher one-year mortality (12.0%, against 1.5% and 4.1%), approximately the same frequency of RH; higher levels of NT-proBNP (by 16.2%, at p = 0.015) and ST-2 (43.0 [38.3 – 47.3] ng/ml, against 41.0 [35.8 – 44.6 ] ng/ml and 41.2 [37.0 – 44.6] ng/ml, with p = 0.004). The NT-proBNP / BNP ratio > 10.17 AU had a higher prognostic value compared to NT-proBNP for PG.Conclusions: In patients with heart failure of ischemic genesis with concomitant atrial fibrillation and diabetes mellitus, the NT-proBNP /ST-2 ratio >17.12 AU has the greatest prognostic value (Se=85.1%; Sp=80.0%). The frequency of RH in this group reaches 97.6% during the year.

  • Open Access

    Clinical and prognostic significance of biomarker ratios in patients with heart failure and concomitant atrial fibrillation and diabetes mellitus

    by N.M. Kulaiets, V.M. Kulaiets

    Background. Heart failure (HF) in combination with atrial fibrillation (AF) and diabetes mellitus (DM) significantly worsens the prognosis of patients, increasing the risk of rehospitali­zations and mortality. Biomarkers such as galectin-3, ST2, brain natriure­tic peptide (BNP), and N-terminal pro-brain natriuretic peptide (NT-proBNP) are associated with myocardial remodeling and inflammation. However, the prognostic significance of their ratios remains uncertain. The purpose was to eva­luate the predictive value of BNP, NT-proBNP, ST2, galectin-3, and their ratios in patients with HF, depending on the presence of AF and/or DM, regarding the risk of rehospitalizations and one-year mortality. Materials and methods. This prospective observational study included 398 patients (mean age 54.3 ± 7.2 years) hospitalized for decompensated HF. They were divided into four groups: HF with sinus rhythm (n = 122), HF with AF (n = 174), HF with DM (n = 50), and HF with both AF and DM (n = 52). Biomarkers were measured using enzyme-linked immunosorbent assay. The primary endpoints were rehospitalization and one-year mortality. Results. Patients with HF and DM had significantly higher levels of galectin-3 (+ 16.7 %, p = 0.003), NT-proBNP (+ 12.5 %, p = 0.015), and ST2 (+ 11.4 %, p = 0.002) compared to those without comorbidities. Individuals with HF, AF, and DM showed even higher NT-proBNP levels (+ 135.0 %, p = 0.0001) and increased NT-proBNP/BNP (+ 170.1 %, p = 0.0001), NT-proBNP/ST2 (+ 145.4 %, p = 0.0001), and NT-proBNP/galectin-3 ratios (+ 135.2 %, p = 0.0001). A reduced ST2/galectin-3 ratio was associated with poorer prognosis. The NT-proBNP/ST2 ratio was the strongest predictor of rehospitalizations (odds ratio 1.82, 95% confidence interval: 1.37–2.41, p = 0.0001). An elevation in ST2 > 41.81 ng/mL (p < 0.0001) and galectin-3 > 2.75 ng/mL (p = 0.0172) was associated with increased one-year mortality. Conclusions. The presence of AF and DM in HF patients is associated with elevated biomarker levels and higher risks of adverse effects. The NT-proBNP/ST2 ratio has significant prognostic value and may guide risk stratification in HF management.

  • Open Access

    The comparative analysis of the influence of bisoprolol and carvedilol on the course of heart failure of ischemic origin in patients with concomitant atrial fibrillation and diabetes mellitus

    by N.M. Kulaiets, V.M. Kulaiets

    Background. The aim of the study was a comparative analysis of bisoprolol and carvedilol effects on the course of heart failure (HF) of ischemic origin in patients with concomitant at­rial fibrillation (AF) and diabetes mellitus (DM). Materials and methods. Three hundred and ninety-eight patients with HF on the background of post-infarction cardiosclerosis aged 58 (54–67) years (198 women and 200 men) were examined. Two hundred and twenty-six (56.8 %) had persistent AF, 102 (25.6 %) had concomitant type 2 DM, and 13.1 % had a combination of DM and AF. One hundred and sixty-seven (42.0 %) patients had a reduced left ventricular ejection fraction (LVEF) ≤ 40 %; 133 (33.4 %) had moderately reduced LVEF (41–49 %); 98 (24.6 %) had preserved LVEF (≥ 50 %). The levels of thyroid-stimulating hormone, free triiodothyronine and free thyroxine, glucose, glycated hemoglobin, galectin-3, suppression of tumorigenicity 2 peptide, B-type natriu­retic peptide, N-terminal prohormone of brain natriuretic peptide were determined. Genotyping was carried out for 4 polymorphisms (rs1801253 and rs1801252 of the β1-АР, rs1042714 of the β2-AP gene, and rs2274273 of the LGALS-3 gene). ECG registration, daily ECG monitoring, standardized echocardiographic exami­nation during hospitalization were carried out. Two hundred and four (51.3 %) patients took bisoprolol in an individually selected dose for a year; 194 (48 %) patients were prescribed carvedilol. According to this criterion, patients were divided into two groups. During one year, the patients were observed, taking into account the presence of repeated hospitalization (RH) due to HF decompensation. Statistical analysis was performed using the programs Statistica for Windows Release 10.0 and MedCalc® (Statistical Software version 22.020). Results. The frequency of RH was lower by 48.3 % (p = 0.040) in the group of patients with HF with reduced LVEF and AF without DM when using carvedilol, compared to the group that took bisoprolol (odds ratio (OR) = 0.412 [0.158–0.976], p = 0.047). If AF is combined with DM in patients with HF (regardless of phenotype), the frequency of RH when treated with carvedilol is lower compared to the group that took bisoprolol (by 21.1 %; p = 0.0018) (OR = 0.096 [0.010–0.937]; p = 0.044). The frequency of RH was also lower in patients with HF with reduced LVEF, under combined AF and DM, when treated with carvedilol (by 27.3 %; p = 0.027) compared to those who took bisoprolol. According to the probit regression analysis, there was an inverse (β = –0.162 ± 0.034) dependence of the probability of RH in patients with sinus rhythm on the severity of heart rate changes (∆HR) during the year of β-AB use. ROC-analysis showed that in patients with HF with sinus rhythm, the risk of RH increa­ses during the observation period when the optimal distribution point for ∆HR ≤ 15.00 min–1 is reached (sensitivity of 80.30 %, specificity of 68.87 %; p < 0.0001). In HF with AF, a S-shaped (sigmoid) dependence (β = 0.507 ± 0.092) was found of the risk of RH on the severity of heart rate changes against the background of β-AB treatment. At the same time, the risk of RH in HF patients with AF increases upon reaching the optimal distribution point for ∆HR > 22.00 min–1 (sensitivity of 98.12 %, specificity of 87.23 %, p < 0.0001). Conclusions. With the use of carvedilol compared to bisoprolol, the risk of RH is lower in HF patients with AF with reduced LVEF (OR = 0.412, p = 0.047) and in patients with a combination of AF and type 2 diabetes (OR = 0.096, p = 0.044). These drugs have the same effectiveness in patients with sinus rhythm, regardless of the HF phenotype and the presence of concomitant DM. During the titration of the β-AB dose in patients with HF with sinus rhythm, it is advisable to gradually decrease the heart rate > 15 min–1; with AF — no more than 22 min–1.

  • Open Access

    Association of β1- and β2-Adrenergic Receptor Gene Polymorphisms with the Effectiveness of Bisoprolol and Carvedilol in Patients with Heart Failure of Ischemic Etiology

    by Nadiia M. Kulaiets, Vira M. Kulaiets

    The aim. To study the relationship between β1-, β2-adrenergic receptor (β-AR) gene polymorphisms and the effectiveness of bisoprolol and carvedilol in patients with heart failure (HF) and coronary heart disease. Materials and methods. We examined 201 patients with HF on the background of post-infarction cardiosclerosis. Control group included 43 healthy individuals of comparable age and sex. Genotyping was carried out for 3 polymorphisms (rs1801253 and rs1801252 of the β1-AR gene; rs1042714 of the β2-AR gene). The patients were divided into 2 groups: the first group included 104 (51.7%) patients who took bisoprolol during the year of observation; 97 (48.3%) patients of the second group were treated with carvedilol. Statistical analysis was performed using Statistica 10.0 and SNPStats programs. Results. In patients with HF, the mutant C-allele (rs1801253 polymorphism) of the β1-AR gene was associated with a decrease in the probability of heart rate reduction >15 min-1 against the background of the use of β-blocker during the year (odds ratio [OR] = 0.42 [0.16-0.98], p = 0.041, recessive inheritance model; OR = 0.62 [0.40-0.97], p = 0.038; log-additive inheritance model). The probability of positive dynamics of the left ventricular ejection fraction (LVEF) increased in carriers of the wild A-allele of the rs1801252 (Ser49Gly) polymorphism of the β1-AR gene (OR = 4.86 [2.35-10.08], p < 0.0001, codominant model; OR = 5.18 [2.51-10.68], p < 0.0001, dominant model; OR = 4.68 [2.26-9.68], p < 0.0001, over-dominant model; OR = 5.05 [2.48-10.28], p < 0.0001, log-additive inheritance model). The probability of an increase in LVEF within a year increased with treatment with carvedilol in homozygous mutant G/G rs1042714 polymorphism (Gln27Glu) of the β2-AR gene in patients with HF (OR = 6.09 [1.16-31.88], p = 0.038, dominant inheritance model). Conclusions. Patients with HF of ischemic etiology, carriers of the mutant C-allele of rs1801253 polymorphism of the β1-adrenoceptor gene, are worse responders to the use of β-blockers compared to patients with the wild G-allele (a lower proportion of patients with a decrease in heart rate >15 min-1: 6.8% vs. 14.5%, respectively; OR = 0.42 [0.16-0.98], p = 0.041). The frequency of an increase in the value of the LVEF >10% was higher compared to patients with the mutant G-allele (39.3% vs. 11.1%, respectively; OR = 4.86 [2.35-10.08], p < 0.0001) against the background of application of β-blockers. The use of carvedilol was more appropriate in homozygous carriers of the mutant G-allele of the rs1042714 polymorphism (Gln27Glu) of the β2-AR gene compared to bisoprolol (a greater proportion of patients with an increase in the LVEF: 17.6% vs. 9.1%, respectively; OR = 6.09 [1.16-31.88], p = 0.038). No probable associations of rs1801253 and rs1801252 polymorphisms of the β1-AR gene with the pharmacodynamics of bisoprolol and carvedilol in patients with HF of ischemic etiology were found.

  • Open Access

    Indicators of functional state of liver, blood lipid spectrum in patients with steatotic liver disease associated with metabolic dysfunction: modern approaches to complex treatment. Review

    by P. R. Herych, V. M. Kulaiets, N. M. Kulaiets

    Objective — to study the dynamics of indicators of the functional state of the liver, the lipid spectrum of the blood, to evaluate the cardiovascular risk according to SCORE‑2 (Systematic Coronary Risk Estimation 2) scale under the influence of complex pathogenetic treatment of the detected disorders in patients with steatotic liver disease associated with metabolic dysfunction (SLDMD) in combination with obesity. Materials and methods. 46 outpatients with a diagnosis SLDMD were examined: 29 (63.1%) men and 17 (36.9%) women aged 32—55 years. The patients were divided into two groups. The main group included 19 (41.3%) persons who received atorvastatin: 20 mg/day for 90 days. The comparison group consisted of 27 (58.7%) patients who were prescribed ursodeoxycholic acid preparations in combination with atorvastatin: 250 mg (15 mg/kg of body weight) for 90 days. The control group consisted of 12 healthy persons of the appropriate age. The anthropometric criterion of obesity was the Quetelet index. Phenotypic variant of obesity was determined by the ratio of waist circumference/hip circumference (WC/HC). Among the patients of the main group, there were 9 (47.4%) persons with I degree of obesity ((32.6±2.2) kg/m2), 6 (31.5%) persons with II degree ( 35.8±3.6 kg/m2), and 4 (21.1%) persons with III degree (40.0±2.1kg/m2), in the comparison group there were 17 (62.9%), 6 (22.3%) and 4 (14.8%) patients, respectively. All patients received a differentiated diet with the calculation of the energy value, the quota of protein (1.4—1.6 g), fat (1.2—1.4 g), carbohydrates (2—3 g) per 1 kg of ideal body weight and dosed physical activity. For assessing the indicators of the functional state of the disease we determined: the level of general bilirubin and its fractions (direct and indirect), activity of serum aminotransferases, alkaline phosphatase, total cholesterol content in the blood serum, high‑density lipoprotein cholesterol, low‑density lipoprotein cholesterol, very‑low‑density lipoprotein cholesterol, triglycerides. Results. In the majority of patients with SLDMD, a statistically significant (p <0.05) increase in the level of direct bilirubin in the blood, the activity of hepatic transaminases, alkaline phosphatase, and changes in the lipid spectrum of the blood were detected. According to the body mass index (BMI) most of the examined patients had visceral obesity. After the course of the combined therapy positive dynamics was marked in biochemical indices of the blood (p <0.05): decrease of the direct bilirubin level, hepatic transaminases, blood phosphatase. The lipid spectrum of the blood was close to normal (p <0.05). The addition of ursodeoxycholic acid to statin therapy contributes to a statistically significant reduction in total cardiovascular risk according to the SCORE 2 scale compared with atorvastatin monotherapy. All patients were recommended to continue the course of treatment (combination of atorvastatin and ursodeoxycholic acid) for 2 to 3 months. Conclusions. The use of a combination of statin and ursodeoxycholic acid in the treatment of patients with SLDMD and obesity helps to normalise the functional state of the liver and blood lipid parameters, reduce the degree of overall cardiovascular risk, and achieve clinical and biochemical remission of the pathological process in the liver.

  • Open Access

    Impact of type 2 diabetes mellitus on heart failure with preserved ejection fraction depending on the presence of atrial fibrillation

    by N.M. Kulaiets, V.M. Kulaiets, O.O. Tkachuk-Hryhorchuk, N.B. Nyshchuk-Oliinyk

    Background. Cardiovascular diseases, including heart failure (HF) and heart failure with preserved ejection fraction (HFpEF), pose a global health challenge. HFpEF is on the rise, especially among the elderly and those with conditions like diabetes, obesity, and hypertension. Type 2 diabetes mellitus (T2DM) often coexists with HFpEF, and atrial fibrillation (AF) further complicates matters due to shared risk factors. The purpose of this study is to comprehensively investigate the influence of type 2 diabetes mellitus on cardiac function and biomarker profiles in patients with heart failure with preserved ejection fraction in the presence or absence of atrial fibrillation. Mate­rials and methods. This was a cohort, single-center study. Four hundred and forty-eight patients with HFpEF were examined. They were divided into 4 groups: group 1 — 189 patients with HFpEF alone; group 2 — 39 patients with HFpEF and T2DM; group 3 — 176 patients with HFpEF and atrial fibrillation; group 4 — 44 patients with HFpEF, AF, T2DM. Results. T2DM may contribute to a slightly older patient population in HFpEF, but age alone is not a primary discriminator. T2DM alone does not substantially impact left ventricular mass index but, when combined with AF, it does. T2DM is associated with an increased left atrial volume index, and AF intensifies this effect. T2DM influences diastolic function, with AF exacerbating it. T2DM affects left ventricular filling pressure, and AF worsens this in HFpEF. T2DM also influences left ventricular systolic function, further compromised when combined with AF in HFpEF patients. Galectin-3 levels are elevated in HFpEF patients with T2DM, further exacerba­ted with AF. NT-proBNP levels are influenced by T2DM and worsened with the combination of AF in HFpEF. SST2 levels are elevated in HFpEF patients with T2DM, further increased with AF, indicating myocardial fibrosis and adverse remodeling. Conclusions. The interaction between T2DM and AF in HFpEF patients creates a synergistic effect, resulting in significant cardiac structural and functional alterations. Novel biomarkers such as galectin-3, NT-proBNP, and sST2 emerge as valuable diagnostic tools, reflecting the complex pathophysiological processes in HFpEF.

  • Open Access

    FEATURES OF THE STRUCTURAL AND FUNCTIONAL STATE OF THE HEART AND NT-proBNP AND sST 2 LEVELS IN PATIENTS WITH HEART FAILURE AND ATRIAL FIBRILLATION

    by N.M. Kulaiets, V.M. Kulaiets, V.N. Seredyuk

    Фібриляція передсердь (ФП) і серцева недостатність (СН) ‒ це медична проблема, яка нерідко пов’язана з різними супутніми захворюваннями та несприятливими наслідками. Мета дослідження. Вивчити особливості структурно-функціонального стану серця та рівнів біомаркерів NT-proBNP і sST 2 у хворих на фібриляцію передсердь із серцевою недостатністю. Матеріали і методи. Обстежено 300 хворих у віці 45-65 років. Усіх пацієнтів було розподілено на групи: I група – хворі з СН і ФП (постійна, або персистуюча форма), (n=150). ІІ ‒ пацієнти без СН із ФП, (n=150). III група – 36 практично здорових осіб. Усім хворим проводили клінічне обстеження, ехокардіографію (ЕхоКГ), визначення рівня NT-proBNP і sST 2 методом імуноферментного аналізу. Результати. У хворих із хронічною СН і ФП найчастіше спостерігаємо дилатацію лівого передсердя, збільшення кінцевого діастолічного й кінцевого систолічного розмірів, кінцевого діастолічного та кінцевого систолічного об’ємів лівого шлуночка, ударного об’єму, зниження фракції викиду, що свідчить про процеси ремоделювання міокарда. Показники рівня NT-proBNP і sST 2 у хворих із ХСН і ФП були достовірно вищими (р<0,05) за аналогічні параметри у пацієнтів без ХСН із ФП. Висновки: У групі хворих на хронічну серцеву недостатність із фібриляцію передсердь показник індексу маси міокарда лівого шлуночка виявився збільшеним у 1,5 рази, порівняно із цим показником у групі хворих без хронічної серцевої недостатності з фібриляцією передсердь. За умови наявності фібриляції передсердь із серцевою недостатністю відзначаємо вірогідне зростання рівнів у крові NT-proBNP і sST 2, порівняно з ізольованою фібриляцією передсердь, які перевищують референті нормативні значення. За умови розвитку серцевої недостатності в пацієнтів із фібриляцією передсердь існують тісні кореляційні зв’язки між структурно-функціональними показниками серця, з одного боку, і NT-pro BNP та чинником «механічного» міокардіального стресу sST 2, з іншого.